Join us on 12-15-2022 for a live seminar about RNA SEQ

Click Here

Alloy Antibody Discovery Services

A fully integrated, precision approach to creating the ideal antibodies to meet your therapeutic goals.
NOT ALL ANTIBODIES ARE CREATED EQUAL

Discover the ideal antibodies for therapeutic intent

Creating antibodies with therapeutic potential requires a precision approach to generating, retrieving, and assessing antibodies with the specific properties required for the intended therapeutic effect.

Start Broader

Campaigns begin by leveraging our ATX-Gx™ humanized mice platform and its broad diversity of the human antibody sequence space. This increases the number of  high-quality, diverse leads against your target of interest.

Screen Smarter

Based on your specific desired functional characteristics and developability requirements, we’ll deploy one of our advanced, AI/ML-enabled technologies for B-cell repertoire mining and sequencing to interrogate and identify the best hits.

Drive to the Finish Line

We convert hits to clinical therapeutic candidates by deploying our full-stack expertise and capabilities to engineer your antibody into a range of formats and conduct in vitro and in vivo functional testing in therapeutically relevant models.

Find the best therapeutic antibody candidate with our modular, customizable discovery approach

Learn More

CORE DISCOVERY MODULE
BISPECIFIC ENGINEERING
AFFINITY MATURATION & PROTEIN ENGINEERING
HUMANIZATION
ML-DRIVEN ENGINEERING & OPTIMIZATION
TRANSLATIONAL MEDICINE
Core Discovery Module
Bispecifics Engineering
Affinity Maturatio/Protein Engineering
Humanization
ML-Driven Eng + Opti
Translational Med
CORE ANTIBODY DISCOVERY MODULE

A choice of two sophisticated, proprietary approaches to screening

We have developed two methodologies for deep screening of immune repertoire to deliver antibodies that meet the specific requirements for your campaign.

SeqImmune™

This sequence-first approach captures the antibody repertoire then zooms in to screen for desired lead. It focuses on the initial diversity of hits and drives functional discovery by downstream assays and iterative mining of immune repertoire—and is well-suited to therapeutic targets without an initial screening assay, benchmark, or screening reagent(s), particularly in exploratory programs.

DeepImmune™

This function-forward approach harnesses functional assays to drive functional relevancy of hits from the get-go. It focuses on the early screening of a specific functional attribute, such as specificity and blocking—and is ideal for therapeutic targets with more understood, well-defined biology and readily available functionally relevant assays with the screening reagents already accessible.

CORE ANTIBODY DISCOVERY MODULE DELIVERABLE

A robust data package empowering you to proceed with qualified leads

Regardless of which path you choose, our industry-leading antibody biophysical characterization package will give you confidence for lead identification. Analytics packages for both SeqImmune and DeepImmune include:

  • Serum titer results
  • Binding kinetics and affinity results
  • Epitope binning results
  • Cell binding assay results
  • Cross-reactivity and specificity
  • Antibody sequence analysis
CASE STUDY

Diverse Antibody Output from the ATX-Gx platform

The ATX-Gx strain produced strong seroconversion levels by immunization with a recombinant protein target antigen.

ATX-GX Platform Produces Wild-Type Seroconversion Levels Resulting in a Highly Diverse Antibody Output
CORE ANTIBODY DISCOVERY MODULE DELIVERABLE

A robust data package empowering you to proceed with qualified leads

Regardless of which path you choose, our industry-leading antibody biophysical characterization package will give you confidence for lead identification. Analytics packages for both SeqImmune and DeepImmune include:

  • Serum titer results
  • Binding kinetics and affinity results
  • Epitope binning results
  • Cell binding assay results
  • Cross-reactivity and specificity
  • Antibody Sequence Analysis
POWERFUL ADD-ONS

Five optional service modules accelerate your drug candidate towards the clinic

Expand your core discovery campaign on your teams with a range of modular, add-on services designed to advance your candidate toward the clinic.

BISPECIFICS DISCOVERY

Advanced format engineering leverages our proprietary in vitro platforms and capabilities

We can generate bispecifics building blocks with our semi-synthetic in vitro human VH library for single domain discovery, our naïve or immune common light chain (CLC) phage libraries (Fab) from ATX-Gx repertoires, and our new ATX-CLC™  transgenic mouse. 

AFFINITY MATURATION

Robust affinity maturation to drive binding affinities to “therapeutic range”

Leveraging our bioinformatics and in vitro methods, we create and screen phage libraries based on the parental clone to find higher-affinity variants.

ANTIBODY HUMANIZATION

Humanizing antibodies from a variety of species

We deploy bioinformatics and a data-driven approach and can humanize rodent mAbs, rabbit mAbs, camelid VHHs—typically within 12 weeks.

ML-DRIVEN ENGINEERING AND OPTIMIZATION

Iterative in vitro and in silico processes mine and harness immune repertoire diversity

This allows rapid engineering of multiple antibody attributes, and can be accessed as an extension of your core antibody discovery project with us or as a standalone project.

TRANSLATIONAL MEDICINE

Preclinical services support functional validation for lead nomination

Our Translational Medicine team runs in vivo functional screening and in vivo proof of concept to generate functional validation data to give you the confidence to move your lead asset forward.

Let’s create your ideal therapeutic antibody together

We’ll craft a tailored discovery approach for optimal outcomes designed to meet your therapeutic objectives.

Accept Privacy Settings Here
We use cookies to enhance your experience while using our website. If you are using our Services via a browser you can restrict, block or remove cookies through your web browser settings. We also use content and scripts from third parties that may use tracking technologies. You can selectively provide your consent below to allow such third party embeds. For complete information about the cookies we use, data we collect and how we process them, please read and Privacy Policy
Youtube
Consent to display content from - Youtube
Vimeo
Consent to display content from - Vimeo
Google Maps
Consent to display content from - Google
Spotify
Consent to display content from - Spotify
Sound Cloud
Consent to display content from - Sound